Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Receivables - Other (2021)

Historic Receivables - Other for Foghorn Therapeutics (FHTX) over the last 1 years, with Q4 2021 value amounting to $300.0 million.

  • Foghorn Therapeutics' Receivables - Other changed N/A to $300.0 million in Q4 2021 from the same period last year, while for Dec 2021 it was $300.0 million, marking a year-over-year change of. This contributed to the annual value of $300.0 million for FY2021, which is N/A changed from last year.
  • Latest data reveals that Foghorn Therapeutics reported Receivables - Other of $300.0 million as of Q4 2021.
  • Over the past 5 years, Foghorn Therapeutics' Receivables - Other peaked at $300.0 million during Q4 2021, and registered a low of $300.0 million during Q4 2021.